108-73-6 | Phloroglucinol

Chemical type

• 1,3,5-Trihydroxybenzene
• Peroxidase inhibitor (PXDN, LPO, TPO)
• Mechanism-based or tight-binding irreversible inhibitor

Key properties

• Most potent inhibitor of PXDN halogenation and peroxidation activity
• Nanomolar IC₅₀ for purified PXDN (0.137 µM in Amplex oxidation assay without bromide)
• IC₅₀ of 0.948 µM in Amplex oxidation assay with bromide
• IC₅₀ of 0.95 µM for inhibiting HOBr-mediated collagen IV cross-linking in decellularized ECM
• IC₅₀ of 1.6 µM for inhibiting collagen IV cross-linking in cell culture
• Forms covalent adduct or tightly binds to PXDN active site, preventing reversion to native enzyme
• Does not form Compound II or III; causes unique spectral changes at 440 nm and 480 nm
• Irreversible inhibition not strictly dependent on preincubation with H₂O₂

• Inhibits PXDN to reduce oxidative stress and inflammation in pathologies
• Potential therapeutic for cardiovascular diseases (e.g., hypertension, atherosclerosis, cardiac fibrosis)
• Potential therapeutic for cancer progression and metastasis
• Potential therapeutic for tissue fibrosis
• Lead compound for designing specific PXDN inhibitors
• Tool for high-throughput screening in PXDN inhibition assays

Classification by use

• Irreversible enzyme inhibitors
• Inhibitors of halogenation cycle in peroxidases
• Antioxidants targeting hypohalous acid production
• Compounds for ECM remodeling studies

A trustworthy factory and manufacturer

1. Peroxidasin Inhibition by Phloroglucinol and Other Peroxidase Inhibitors, Antioxidants, 2024, 13(1), 23